What Happened to IP Group plc Shares on 13 November 2026?

IP Group plc (LSE:IPO) shares eased 2.90% to 73.7p on 13 November 2026. The science and technology investor was in focus following its half-yearly results for the six months ended 30 June 2026, published on 15 September 2026.

The results reported higher net asset value, a profit for the period and a series of milestones across its health technology and Clean Technology holdings.

Key Highlights

Net asset value rose to £1,006.4m, equivalent to 113.9p per share, a 3.2% increase from 110.4p at the end of 2025. Management said net asset value per share had subsequently risen to approximately 117p by September.

The group reported a profit for the period of £31.2m. Its valuation of the Pfizer Obesity Royalty Income asset rose by £27m to £152m after further clinical progress.

About IP Group plc

IP Group invests in breakthrough science and technology companies, with a focus on spin-outs from leading universities. Its portfolio has included Oxford Nanopore Technologies, Hinge Health, Featurespace, First Light Fusion, Hysata and Oxa.

The group is listed on the London Stock Exchange and also manages third-party Capital alongside its own balance sheet.

Health Technology Milestones

Centessa was acquired by Eli Lilly, generating a £7.3m value uplift for the group. Enterprise Therapeutics reported positive Phase 2 results in cystic fibrosis, and Microbiotica reported positive Phase 1b results in ulcerative colitis.

Istesso also started a Phase 2 trial in rheumatoid arthritis during the period.

Clean Technology Progress

First Light Fusion completed a £25m funding round and Mantle8 completed a €31m round. Hysata secured its first binding megawatt-scale commercial electrolyser order, with delivery expected in the first half of 2027.

Hysata develops hydrogen electrolyser technology that it describes as highly efficient.

Technology and Autonomy

Quantum Motion, Quantum Circuits and Oxa all completed financing rounds in the period. Oxa also formed a joint venture with the Dubai Future Foundation, called Shift, intended to deploy autonomous vehicles in ports and airports.

These rounds show continued investor interest in the group's technology holdings.

Pfizer Obesity Royalty

The Pfizer Obesity Royalty Income asset is described as one of the most significant drivers of value in the group. Management said further positive clinical data for the programme supported the uplift in valuation.

The group uses probability-weighted valuations for this royalty asset, reflecting the stages of clinical development.

Understanding Net Asset Value

Net asset value is the value of a company's Assets less its liabilities, and for an Investment company it is largely the value of its portfolio holdings. Per-share net asset value divides that total by the number of shares in issue.

Realisations refer to the sale of holdings for cash, which converts portfolio value into proceeds that can be reinvested or returned to shareholders.

Why the Update Matters for the Sector

Investors in early-stage science companies are followed for how portfolio valuations, funding rounds and exits come together. IP Group's update illustrates how milestones in different sectors feed into reported net asset value.

The mix of health, clean technology and digital holdings provides breadth across themes.

Key Growth Catalysts

Clinical and commercial milestones across the portfolio, further funding rounds and cash realisations are the main supports for value. The royalty asset provides a long-dated income-linked holding.

Third-party capital management adds a further activity alongside the Balance Sheet portfolio.

Factors to Monitor

Portfolio valuations depend on funding conditions, clinical outcomes and the pace of commercialisation. Listed holdings are also affected by market movements.

Timing of exits can vary between periods.

What Investors Should Watch Next

Investors may wish to follow net asset value per share, cash realisations, funding rounds across the portfolio, clinical milestones and the next set of results.

Conclusion

IP Group plc (LSE:IPO) eased 2.90% to 73.7p on 13 November 2026. IP Group reported net asset value above £1bn, a 3.2% rise in net asset value per share and progress across its portfolio. The next trading and results updates are the points of reference.